Variable | Statistic |
---|---|
Age, years | 54.0 (47.9, 63.0) |
Sex, female | 34 (59%) |
RA disease durations, months†| 18.8 (11.3, 35.9) |
Pain (0 to 100 mm) | 30 (16, 69) |
Patient global assessment (0 to 100 mm) | 28.5 (12, 63) |
Morning stiffness duration, minutes | 30 (15, 90) |
HAQ disability index (0 to 3) | 0.5 (0.1, 1.4) |
RF positive‡ | 53 (93%) |
ACPA positive§ | 44 (80%) |
C-reactive protein, mg/L | 5.9 (3.0, 11.1) |
CMV IgG positive | 28 (48%) |
EBV IgG positive | 55 (95%) |
DAS28 | 4.4 (3.4, 5.4) |
Radiographic damage scores (SHS), units | Â |
   Total | 18.5 (8, 37) |
   Erosions | 11.5 (3, 30) |
   Joint space narrowing | 4.5 (3, 12) |
Medications | Â |
   Methotrexate | 49 (86%) |
   Biologic response modifiers | 14 (24%) |
   Corticosteroids | 27 (47%) |